vs

Side-by-side financial comparison of Moderna (MRNA) and SLM Corp (SLM). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $560.0M, roughly 1.8× SLM Corp). SLM Corp runs the higher net margin — 55.0% vs -19.7%, a 74.7% gap on every dollar of revenue. Over the past eight quarters, SLM Corp's revenue compounded faster (22.7% CAGR vs -45.0%).

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Nikon SLM Solutions AG, headquartered in Lübeck, Germany, is a manufacturer of 3D metal printers listed on the stock market and co-owner of the word mark SLM. The shares of SLM Solutions Group AG have been listed in Prime Standard of the Frankfurt Stock Exchange since May 9, 2014.

MRNA vs SLM — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.8× larger
MRNA
$1.0B
$560.0M
SLM
Higher net margin
SLM
SLM
74.7% more per $
SLM
55.0%
-19.7%
MRNA
Faster 2-yr revenue CAGR
SLM
SLM
Annualised
SLM
22.7%
-45.0%
MRNA

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
MRNA
MRNA
SLM
SLM
Revenue
$1.0B
$560.0M
Net Profit
$-200.0M
$308.0M
Gross Margin
79.6%
Operating Margin
-25.6%
69.6%
Net Margin
-19.7%
55.0%
Revenue YoY
-45.4%
Net Profit YoY
-1638.5%
1.0%
EPS (diluted)
$-0.51
$1.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRNA
MRNA
SLM
SLM
Q1 26
$560.0M
Q4 25
$377.1M
Q3 25
$1.0B
$373.0M
Q2 25
$376.8M
Q1 25
$375.0M
Q4 24
$966.0M
$362.2M
Q3 24
$1.9B
$359.4M
Q2 24
$372.2M
Net Profit
MRNA
MRNA
SLM
SLM
Q1 26
$308.0M
Q4 25
$233.2M
Q3 25
$-200.0M
$135.8M
Q2 25
$71.3M
Q1 25
$304.5M
Q4 24
$-1.1B
$111.6M
Q3 24
$13.0M
$-45.2M
Q2 24
$252.0M
Gross Margin
MRNA
MRNA
SLM
SLM
Q1 26
Q4 25
Q3 25
79.6%
Q2 25
Q1 25
Q4 24
23.5%
Q3 24
72.4%
Q2 24
Operating Margin
MRNA
MRNA
SLM
SLM
Q1 26
69.6%
Q4 25
83.8%
Q3 25
-25.6%
49.8%
Q2 25
23.3%
Q1 25
Q4 24
-129.0%
36.5%
Q3 24
-3.8%
-16.6%
Q2 24
91.0%
Net Margin
MRNA
MRNA
SLM
SLM
Q1 26
55.0%
Q4 25
61.8%
Q3 25
-19.7%
36.4%
Q2 25
18.9%
Q1 25
81.2%
Q4 24
-115.9%
30.8%
Q3 24
0.7%
-12.6%
Q2 24
67.7%
EPS (diluted)
MRNA
MRNA
SLM
SLM
Q1 26
$1.54
Q4 25
$1.11
Q3 25
$-0.51
$0.63
Q2 25
$0.32
Q1 25
$1.40
Q4 24
$-2.91
$0.53
Q3 24
$0.03
$-0.23
Q2 24
$1.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRNA
MRNA
SLM
SLM
Cash + ST InvestmentsLiquidity on hand
$1.1B
$5.2B
Total DebtLower is stronger
$6.2B
Stockholders' EquityBook value
$9.3B
$2.4B
Total Assets
$12.1B
$29.4B
Debt / EquityLower = less leverage
2.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRNA
MRNA
SLM
SLM
Q1 26
$5.2B
Q4 25
$4.2B
Q3 25
$1.1B
$3.5B
Q2 25
$4.1B
Q1 25
$3.7B
Q4 24
$1.9B
$4.7B
Q3 24
$1.6B
$4.5B
Q2 24
$5.3B
Total Debt
MRNA
MRNA
SLM
SLM
Q1 26
$6.2B
Q4 25
$5.4B
Q3 25
$6.8B
Q2 25
$6.4B
Q1 25
$6.1B
Q4 24
$6.4B
Q3 24
$6.0B
Q2 24
$5.4B
Stockholders' Equity
MRNA
MRNA
SLM
SLM
Q1 26
$2.4B
Q4 25
$2.5B
Q3 25
$9.3B
$2.3B
Q2 25
$2.4B
Q1 25
$2.4B
Q4 24
$10.9B
$2.2B
Q3 24
$11.9B
$2.1B
Q2 24
$2.3B
Total Assets
MRNA
MRNA
SLM
SLM
Q1 26
$29.4B
Q4 25
$29.7B
Q3 25
$12.1B
$29.6B
Q2 25
$29.6B
Q1 25
$28.9B
Q4 24
$14.1B
$30.1B
Q3 24
$15.8B
$30.0B
Q2 24
$28.8B
Debt / Equity
MRNA
MRNA
SLM
SLM
Q1 26
2.53×
Q4 25
2.19×
Q3 25
2.92×
Q2 25
2.70×
Q1 25
2.56×
Q4 24
2.98×
Q3 24
2.83×
Q2 24
2.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRNA
MRNA
SLM
SLM
Operating Cash FlowLast quarter
$-847.0M
Free Cash FlowOCF − Capex
$-880.0M
FCF MarginFCF / Revenue
-86.6%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRNA
MRNA
SLM
SLM
Q1 26
Q4 25
$-64.5M
Q3 25
$-847.0M
$-49.3M
Q2 25
$-138.7M
Q1 25
$-146.1M
Q4 24
$825.0M
$4.5M
Q3 24
$-1.6B
$-113.4M
Q2 24
$-143.8M
Free Cash Flow
MRNA
MRNA
SLM
SLM
Q1 26
Q4 25
Q3 25
$-880.0M
Q2 25
Q1 25
Q4 24
$303.0M
Q3 24
$-1.7B
Q2 24
FCF Margin
MRNA
MRNA
SLM
SLM
Q1 26
Q4 25
Q3 25
-86.6%
Q2 25
Q1 25
Q4 24
31.4%
Q3 24
-92.2%
Q2 24
Capex Intensity
MRNA
MRNA
SLM
SLM
Q1 26
Q4 25
Q3 25
3.2%
Q2 25
Q1 25
Q4 24
54.0%
Q3 24
8.1%
Q2 24
Cash Conversion
MRNA
MRNA
SLM
SLM
Q1 26
Q4 25
-0.28×
Q3 25
-0.36×
Q2 25
-1.95×
Q1 25
-0.48×
Q4 24
0.04×
Q3 24
-120.46×
Q2 24
-0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

SLM
SLM

Net Interest Income$375.0M67%
Noninterest Income$185.0M33%

Related Comparisons